Gain Therapeutics’ Post

Today is the last day of #SfN2023 and the final call to view the latest data on how our ioCells™ are empowering CNS drug discovery! Learn how our ioDisease Model Cells™ for Huntington's disease and amyotrophic lateral sclerosis (ALS) are being used to model neurodegeneration in vitro, to support CNS drug discovery programs at Charles River Laboratories. Poster 467.12 | Establishing a hPSC-derived Huntington’s disease neuronal model suitable for phenotypic drug screening and to identify small molecule modulators of mutant HTT Session: Huntington’s Disease: Molecular and Cellular Mechanisms Time: 11 am - 12 pm Larissa Butler et al, Charles River Laboratories Poster 533.19 | TDP-43 dysfunction and STMN-2 mis-splicing upon proteasomal inhibition in iPSC derived neuronal ALS model Session: ALS: Patient Research and Human-derived Cellular Models Time: 4 - 5 pm Dario Magnani et al, Charles River Laboratories We are also excited to showcase our newest products in the market ioMotor Neurons™ and ioSensory Neurons™! Join the poster sessions to discover the functional data presented by our scientific experts! Poster 489.02 | Rapid and consistent generation of functional motor neurons from reprogrammed human iPSCs using opti-ox technology Session: Motor Neurons: Development, Identification, Intrinsic Properties and Modulation Time : 9 - 10 am Marcos Herrera Vaquero et al, bit․bio Poster 544.05 | Optimised and scalable reprogramming of human iPSCs to generate nociceptor sensory neurons for the study of pain mechanisms and neuropathies Session: Behavioural and Physiological Pain Models Time: 1 - 2 pm Tony Oosterveen, bit․bio View the full agenda: https://hubs.ly/Q028_5kr0 Come meet our scientists at booth 2001! #research #DrugDiscovery #optiox #ioCells #iPSC #neuroscience #HTS #neuron #array #data #microglia #neurodegeneration #ALS #HuntingtonsDisease

Wang Liqun has always been fascinated by neuroscience. Early in her career, she did basic biomedical research to better understand a rare neurodegenerative disease called Alexander Disease. This left her wondering, “What can I do to really help these patients?” After spending time in industry, she joined the Wyss Institute’s #BrainTargetingProgram to develop technologies to better deliver drugs to the brain. Learn more about Liqun and her work in this month’s Humans of the Wyss.  #HOWyss #DrugDelivery #NeurodegenerativeDisease #BrainCancer #BrainResearch https://lnkd.in/gEbv8Qt2

Our axoCells™ Astrocytes line (ax0704) is designed to fuel robust in vitro models for neurodegenerative disease research and drug discovery. With labs around the world increasingly moving to in vitro models, drug discovery researchers are embracing human iPSC-derived cells to build more human, more functional models for neuroscience. But with many labs still using rat astrocytes for their work (with very long protocols, some even >100 days), we're "supporting the switch" to human iPSCs with our axoCells Astrocytes product that can drive faster, cheaper in vitro workflows. Key highlights of our axoCells Astrocytes product include: • Best price on the market • Derived from fibroblasts taken from a healthy 40-50-year-old male donor • Assay ready in just 48 hours • Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin • Specifically developed for use in powerful in vitro monoculture models and complex co-culture systems for drug discovery Click here to read more about this product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://hubs.la/Q02H3-SF0 Want to explore the details and get a quote? Click here: https://hubs.la/Q02H3Rb_0 #iPSCs #Astrocytes #AlzheimersDisease #ParkinsonsDisease #ALS #DrugDiscovery

Our axoCells™ Astrocytes line (ax0704) is designed to fuel robust in vitro models for neurodegenerative disease research and drug discovery. With labs around the world increasingly moving to in vitro models, drug discovery researchers are embracing human iPSC-derived cells to build more human, more functional models for neuroscience. But with many labs still using rat astrocytes for their work (with very long protocols, some even >100 days), we're "supporting the switch" to human iPSCs with our axoCells Astrocytes product that can drive faster, cheaper in vitro workflows. Key highlights of our axoCells Astrocytes product include: • Best price on the market • Derived from fibroblasts taken from a healthy 40-50-year-old male donor • Assay ready in just 48 hours • Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin • Specifically developed for use in powerful in vitro monoculture models and complex co-culture systems for drug discovery Click here to read more about this product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://hubs.la/Q02H3DrG0 Want to explore the details and get a quote? Click here: https://hubs.la/Q02H44NX0 #iPSCs #Astrocytes #AlzheimersDisease #ParkinsonsDisease #ALS #DrugDiscovery

"The initiation of this clinical trial is a major milestone in Aspen's mission to develop and deliver personalized, regenerative neurologic therapies for people with unmet medical needs, starting with Parkinson's disease," said Damien McDevitt, PhD, Aspen Neuroscience President and Chief Executive Officer. "To date, there is no disease-modifying therapy that can stop, replace or prevent the loss of dopamine neurons or slow the progression of Parkinson's." "This first-in-human trial holds significant promise to investigate the ability of ANPD001 to improve the lives of people with moderate to advanced Parkinson's disease," said Edward Wirth III, MD, PhD, Chief Medical Officer of Aspen Neuroscience. "Our 2022 Trial Ready Cohort Screening Study has completed enrollment, and we plan to dose patients in the ASPIRO Phase 1/2a study this year." https://lnkd.in/gHK_sDrM

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies - FENS Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease Data demonstrates improvement in cognitive function in GBA1 hashtag #Parkinson’s disease model in addition to reversal of motor function deficits https://lnkd.in/gnzP6jg2

NEW PRODUCT ALERT! axoCells ASTROCYTES Key highlights of our new axoCells Astrocytes product include: • Best price on the market • Derived from fibroblasts taken from a healthy 40-50-year-old male donor • Assay ready in just 48 hours • Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin • Specifically developed for use in powerful in vitro monoculture models and complex co-culture systems for drug discovery Bolstered by our world-leading ISO 9001-accredited manufacturing processes, we are delighted to pass on further cost savings to you. Our new ax0704 astrocytes are cheaper than previous astrocytes and are priced at just £660 / $830 / €770 per vial (1 million cells)- the best price on the market! Click here to read more about this new product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://hubs.la/Q02BjWkX0 Want to explore the details and get a quote? Click here: https://hubs.la/Q02BjWpy0 #drugdiscovery #drugdevelopment #ipsc #cellculture #biopharma #neuroscience #biotech #stemcells #humancells #pharma #MPS #organoids

Development of compounds protecting neuronal cells from damage is key to the treatment of stroke and neurodegenerative diseases, an area of highly unmet medical need. Please visit our latest work, 'Novel SK Channel Positive Modulators Prevent Ferroptosis and Excitotoxicity in Neuronal Cells', a comprehensive study that marks a significant step forward in neurological research and drug development. Access the full manuscript here: https://lnkd.in/ejYQ4GCr 🔍 Our Research Highlights: > Structure based design and synthesis of innovative SK2 channel modulators > Providing new insights into their protective mechanisms against ferroptosis and excitotoxicity. > Empirical evidence showing that these compounds preserve mitochondrial function and increase SK2 channel activity, pointing towards a new horizon in neuroprotective strategies. > Detailed pharmacological analysis demonstrating the superior efficacy of these compounds in comparison to well-established SK modulators. 🧠 Why It Matters: Neurological diseases pose a complex challenge, often involving intricate mechanisms like ferroptosis (a form of programmed cell death) and excitotoxicity (neuronal damage due to excessive stimulation). Our findings illuminate the path towards innovative treatments, offering hope in the battle against debilitating conditions such as stroke, Alzheimer’s, Parkinson’s, and ALS. 🤝 Collaboration and Acknowledgements: This work was made possible through the collaboration of our dedicated team of scientists of the groups of Dömling (compound design, synthesis), Dolga (in vitro pharmacology) and Decher (in vivo pharmacology). Let's continue to push the boundaries of scientific discovery and improve the lives of those affected by neurological diseases! #Neuroscience #Neuroprotection #SKChannels #Ferroptosis #Excitotoxicity #ScientificResearch #Innovation #Collaboration #DrugDevelopment #NeurologicalDiseases #ALS #Parkinsons #Alzheimers #ScientificBreakthrough #researchimpacteu #researchimpact

Next week is #AAIC24! Join our Co-Founder & CEO, Damian Wheeler, PhD, and expert Chase Redd as they present tools, technologies, and #3Dhistology techniques that are furthering Alzheimer's research. We're showcasing two posters: • Poster #841 (Abstract ID 95666), “Brain-Wide Cellular-Resolution Measurement of Antibody Therapeutic Biodistribution” on Sunday, July 28th • Poster #874 (Abstract ID 95690), “Brain-Wide Cellular-Resolution Quantification of Amyloid Plaques and Microglia in AD Model Mice” on Tuesday, July 30th These posters highlight how tissue clearing and light sheet microscopy methods enable unbiased, brain-wide analysis of therapeutics and neuroinflammation, offering cellular resolution measurements of BBB penetration of antibody therapeutics and providing AI-powered quantification of #amyloidplaques and #microglia across entire mouse brains. Join us at #AAIC2024 to learn more about how #tissueclearing and #lightsheet #microscopy advances can accelerate pre-clinical CNS therapeutic development and shape the future of #AlzheimersDisease research. We're looking forward to engaging with fellow researchers and advancing our collective understanding of Alzheimer's disease. #Neuroscience, #AlzheimersResearch, #Biotech, #Innovation, #CNSDrugDevelopment, Alzheimer's Association®

We've had a fantastic response to our newest product! Make sure to check out the fastest and most affordable human iPSC-derived astrocytes on the market! We recently announced our new axoCells™ Astrocytes line (ax0704) designed to fuel robust in vitro models for neurodegenerative disease research and drug discovery. With labs around the world increasingly moving to in vitro models, drug discovery researchers are embracing human iPSC-derived cells to build more human, more functional models for neuroscience. But with many labs still using rat astrocytes for their work (with very long protocols, some even >100 days), we're "supporting the switch" to human iPSCs with this new axoCells Astrocytes product that can drive faster, cheaper in vitro workflows. Key highlights of our new axoCells Astrocytes product include: • Best price on the market • Derived from fibroblasts taken from a healthy 40-50-year-old male donor • Assay ready in just 48 hours • Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin • Specifically developed for use in powerful in vitro monoculture models and complex co-culture systems for drug discovery Bolstered by our world-leading ISO 9001-accredited manufacturing processes, we are delighted to pass on further cost savings to you. Our new ax0704 astrocytes are cheaper than previous astrocytes and are priced at just £660 / $830 / €770 per vial (1 million cells)- the best price on the market! Click here to read more about this new product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://hubs.la/Q02BjWkX0 Want to explore the details and get a quote? Click here: https://hubs.la/Q02BjWpy0 #iPSCs #Astrocytes #AlzheimersDisease #ParkinsonsDisease #ALS #DrugDiscovery